Performance of the CLEO III LiF-TEA Ring Imaging Cherenkov Detector in a High Energy Muon Beam

The CLEO III Ring Imaging Cherenkov detector uses LiF radiators to generate Cherenkov photons which are then detected by proportional wire chambers using a mixture of CH$_4$ and TEA gases. The first two photon detector modules which were constructed, were taken to Fermilab and tested in a beam dump that provided high momentum muons. We report on results using both plane and sawtooth shaped radiators. Specifically, we discuss the number of photoelectrons observed per ring and the angular resolution. The particle separation ability is shown to be sufficient for the physics of CLEO III

Successful Treatment of Ibrutinib-Associated Central Nervous System Hemorrhage with Platelet Transfusion Support

Ibrutinib is a novel targeted therapy for B-cell malignancies. Hemorrhagic events were reported in the original trials, however the mechanism of bleeding is just being elucidated. Recent studies have demonstrated platelet dysfunction as a mechanism of bleeding. Currently we report two patients who developed life-threatening central nervous system hemorrhage while receiving ibrutinib for chronic lymphoid leukemia (CLL) and mantle cell lymphoma, respectively. Both patients improved rapidly after platelet transfusions even though their platelet counts were normal or only mildly reduced at the time of hemorrhage. We suggest that platelet transfusions can ameliorate the platelet dysfunction defect of ibrutinib and can support the patient through the critical period until new platelet production occurs

Stroke following percutaneous coronary intervention : type-specific incidence, outcomes and determinants seen by the British Cardiovascular Intervention Society 2007-12

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: [email protected] reviewedPostprin

The CLEO-III Ring Imaging Cherenkov Detector

The CLEO-III Detector upgrade for charged particle identification is discussed. The RICH design uses solid LiF crystal radiators coupled with multi-wire chamber photon detectors, using TEA as the photosensor, and low-noise Viking readout electronics. Results from our beam test at Fermilab are presented.Comment: Invited talk by R.J. Mountain at ``The 3rd International Workshop on Ring Imaging Cherenkov Detectors," a research workshop of the Israel Science Foundation, Ein-Gedi, Dead-Sea, Israel, Nov. 15-20, 1998, 14 pages, 9 figure

High platelet reactivity in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Randomised controlled trial comparing prasugrel and clopidogrel

Background: Prasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coronary syndromes. Data available on prasugrel reloading in clopidogrel treated patients with high residual platelet reactivity (HRPR) i.e. poor responders, is limited. Objectives: To determine the effects of prasugrel loading on platelet function in patients on clopidogrel and high platelet reactivity undergoing percutaneous coronary intervention for acute coronary syndrome (ACS). Patients: Patients with ACS on clopidogrel who were scheduled for PCI found to have a platelet reactivity ≥40 AUC with the Multiplate Analyzer, i.e. “poor responders” were randomised to prasugrel (60 mg loading and 10 mg maintenance dose) or clopidogrel (600 mg reloading and 150 mg maintenance dose). The primary outcome measure was proportion of patients with platelet reactivity <40 AUC 4 hours after loading with study medication, and also at one hour (secondary outcome). 44 patients were enrolled and the study was terminated early as clopidogrel use decreased sharply due to introduction of newer P2Y12 inhibitors. Results: At 4 hours after study medication 100% of patients treated with prasugrel compared to 91% of those treated with clopidogrel had platelet reactivity <40 AUC (p = 0.49), while at 1 hour the proportions were 95% and 64% respectively (p = 0.02). Mean platelet reactivity at 4 and 1 hours after study medication in prasugrel and clopidogrel groups respectively were 12 versus 22 (p = 0.005) and 19 versus 34 (p = 0.01) respectively. Conclusions: Routine platelet function testing identifies patients with high residual platelet reactivity (“poor responders”) on clopidogrel. A strategy of prasugrel rather than clopidogrel reloading results in earlier and more sustained suppression of platelet reactivity. Future trials need to identify if this translates into clinical benefit